Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Express Scripts
Cantor Fitzgerald
Daiichi Sankyo
AstraZeneca
Argus Health
Mallinckrodt
McKesson
Dow

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,417,175

« Back to Dashboard

Which drugs does patent 6,417,175 protect, and when does it expire?

Patent 6,417,175 protects TEFLARO and is included in one NDA.

This patent has twenty patent family members in sixteen countries.
Summary for Patent: 6,417,175
Title: Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Abstract:A novel cephem compound of the formula: ##STR1## wherein R.sup.1 is a phosphono group or a group convertible to a phosphono group; R.sup.2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH.sub.2 ; n is 0 or 1; one of R.sup.3 and R.sup.4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R.sup.3 and R.sup.4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
Inventor(s): Ishikawa; Tomoyasu (Otsu, JP), Hashiguchi; Shohei (Toyonaka, JP), Iizawa; Yuji (Muko, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/555,949
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,417,175

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-001 Oct 29, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHODS FOR TREATING BACTERIAL INFECTIONS ➤ Sign Up
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-002 Oct 29, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHODS FOR TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,417,175

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-351499Dec 19, 1997
PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/JP98/05709
PCT Publication Date:July 01, 1999PCT Publication Number: WO99/32497

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKinsey
Federal Trade Commission
Teva
Chubb
Citi
Mallinckrodt
Boehringer Ingelheim
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.